

Printed as of 12/14/2025

Hospital Albert Einstein

Disclosures

Personal Commercial (12)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Ache	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
AMGEN	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Amryt	Speaker's Bureau	Modest (< \$5,000)	Prevention
Biolab	Speaker's Bureau	Modest (< \$5,000)	Prevention
Eli Lilly and Company	Speaker's Bureau	Modest (< \$5,000)	Prevention
Esperion	Research/Research Grants	Modest (< \$5,000)	Prevention
Kowa	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Libbs	Speaker's Bureau	Significant (>= \$5,000)	Prevention Vascular Medicine
Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention Vascular Medicine
Novo-Nordisk	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
PTC	Consultant Fees/Honoraria	Modest (< \$5,000)	Vascular Medicine
Sanofi/Regeneron	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (6)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Amgen	Research/Research Grants ‡ Hauser	Modest (< \$5,000)	Prevention
Atherosclerosis	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Prevention
European Journal of Preventive Cardiology	Other - Associate Editor	None (\$0)	Prevention
International Atherosclerosis Society	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Prevention
Journal of Clinical Lipidology	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Prevention
Sanofi/Regeneron	Research/Research Grants ‡ Odyssey Pediatric	None (\$0)	Prevention

Clinical Trial Enroller (6)

Trial Name	Trial Sponsor	Trial Funding Source
HAUSER	Amgen	Amgen Inc.
Ocean study	Amgen	
PROMINENT	Kowa	Kowa
HORIZON	Novartis Corporation	Novartis Corporation
ORION-16	Novartis Corporation	Novartis Corporation
ODYSSEY KIDS	SANOFI	Sanofi-Aventis

Institutional Financial Decision-Making Role (0)

No disclosures on record

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/20/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement in the properties of the

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/20/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 9/20/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 9/20/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.